Anti-Infective Drugs Market size is $108.8Bn in 2019, growing at a CAGR of 4.1% during the forecast period 2020-2025. Anti-Infective Drugs are medicine that is capable of inhibiting the spread of an infectious organism or by killing the infectious organism outright. This term includes antibiotics, antifungals, anthelmintics, antimalarials, antiprotozoals, antituberculosis agents, and antivirals. It treats minor infections and most often cure many serious infectious diseases, like pneumonia or tuberculosis. The anti-infective agents have distinct mechanism of action which includes the inhibition of DNA synthesis and kill the cellular component hence prevent it from replication. The increasing population of viral infections such as respiratory syncytial virus as well as influenza and high adoption of anti-infective therapies is driving the growth of the market
By Indication – Segment Analysis
In 2019, HIV Infections segment dominated the Anti-Infective Drugs Market in terms of revenue is estimated to grow at a CAGR of 5.2%. It is an infectious virus that damages the cells in your immune system and weakens the ability to fight everyday infections and disease. HIV spreads through unprotected sex with an infected person and spread by sharing drug needles or through contact with the blood of a person who has HIV. HIV harms the immune system by destroying the white blood cells that fight infection. The increasing access to effective HIV prevention, diagnosis, treatment, and care, including for opportunistic infections, it has become a manageable chronic health condition, enabling people living with HIV to lead long and healthy lives. According to WHO, in 2019, 68% of adults and 53% of children living with HIV globally were receiving lifelong antiretroviral therapy (ART) abetting towards the growth of the market.
Request for Sample of the Report @ https://www.industryarc.com/pdfdownload.php?id=15693
Report Price: $ 4500 (Single User License)
By Geography – Segment Analysis
In 2019, the North America region dominated Anti-Infective Drugs Market in terms of revenue with a market share of more than 34% owing towards well-spread awareness of anti-infective drugs among end-users such as health care professionals and clinicians coupled with the presence of developed health care infrastructure in the region. Several government initiatives and high awareness in developed geographies including the U.S., private partnership projects and rising cost containment initiatives by drug manufacturers are the other factors augmenting the market growth. Major players are focusing on the development of new drugs for the treatment of HIV and other infectious diseases in this region, therefor, are the key factors in the growth of the Anti-Infective Drugs market. Asia-Pacific is projected to record the fastest growth rate during the forecast period 2020-2025.
Drivers – Anti-Infective Drugs Market
Rising R&D Initiatives
The programs like Innovative Medicines Initiative’s (IMI’s), New Drugs for Bad Bugs (ND4BB) program, Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), and Biomedical Advanced Research and Development Authority’s (BARDA) Broad Spectrum Antimicrobials Program have been implemented for the development of novel antibiotics by focusing on R&D gaps. Similarly, Global Antibiotic Research and Development Partnership (GARDP) set up by the World Health Organization (WHO) and the Drugs for Neglected Diseases Initiative (DNDi) in May 2016 is further providing support to the R&D initiatives globally thereby propelling the Anti-Infective drugs market.
Talk to one of our sales representative about the full report by providing your details in the link below:
Challenges – Anti-Infective Drugs Market
Supply Shortages of Anti-Infective Drugs
The shortage of supply for anti-infective drugs can be attributed to low profits margins in the industry and exit strategies adopted by the market players is anticipated restrains the market’s growth. Also, major antibiotics companies such as Novartis, AstraZeneca and others are paying less attention on their antibiotic research operations owing to the lack of profitability, which further results in the shortage of drugs and thus hampering the anti-infective drugs market.
Anti-Infective Drugs Industry Outlook
Product Launches was the key strategy of the players in the Anti-Infective Drugs Industry. Anti-Infective Drugs top 10 companies include Abbott Laboratories, Alcon Pharmaceuticals Ltd., Quest Diagnostics Inc., AstraZeneca Plc., Bayer HealthCare AG, Bristol-Myers Squibb Co., Boehringer Ingelheim, Sanofi-Aventis SA, Novartis AG and GlaxoSmithKline Plc.
In January 2020, Novartis AG acquired The Medicines Company. This acquisition helped in the treatment of the world’s leading cause of mortality and disability with a vaccine-like approach.
In May 2016, Quest Diagnostics Inc. launched three new cancer test (MYvantage™ 34-gene Hereditary, GIvantage™ Hereditary and Qvantage™ Hereditary) services designed to provide clinically actionable insight into an individual’s risk of developing hereditary forms of cancer.
The increasing prevalence of diseases like malaria, chikungunya, and chagas disease is likely to be the major driving factor for the market’s growth.
Rise in the number of hospitals and primary care clinics are adding towards the market’s growth.
Asia-Pacific region is set to record the fastest growth rate during the forecast period 2020-2025.
Related Reports :
A. Antibiotics Drugs Market
B. Infection prevention & Control Market
About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to email@example.com to discuss more about our consulting services.